On the heels of GW's epilep­sy win, Wall Street dar­ling Zo­genix shares pos­i­tive PhI­II da­ta on ri­val drug

A ri­val is al­ready loom­ing for GW Phar­ma­ceu­ti­cals $GW­PH, the drug­mak­er who scored the very first cannabis-de­rived drug ap­proval on­ly weeks ago to treat rare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.